Literature DB >> 9279723

Procalcitonin as a marker of bacterial sepsis in patients infected with HIV-1.

Y Gérard1, D Hober, M Assicot, S Alfandari, F Ajana, J M Bourez, C Chidiac, Y Mouton, C Bohuon, P Wattre.   

Abstract

Procalcitonin (ProCT) is a recently described marker of severe sepsis. It was decided to assess the value of proCT as a marker of secondary infection in patients infected with HIV-1. ProCT plasma levels were measured by immunoluminometric assay in a prospective study in 155 HIV-infected individuals: 102 asymptomatic and 53 with lever or suspected secondary infections. The baseline plasma level of ProCT was low (0.5 ng/ml +/- 0.37), even in the latest stages of the disease, and did not differ from the values of healthy subjects (0.54 ng/ml +/- 0.08). EDTA-treated whole blood was collected from patients before starting specific antimicrobial therapy. No elevation of ProCT level was detected in HIV-infected patients with evolving secondary infections including PCP (n = 4), cerebral toxoplasmosis (n = 4), viral infections (n = 9), mycobacterial infections (n = 5), localized bacterial (n = 12) and fungal infections (n = 4), malignancies (n = 3), and in various associated infectious and non-infectious febrile events (n = 13). All these plasma values were lower than 2.1 ng/ml. In contrast, high ProCT plasma levels were detected in one HIV-infected patient with a septicaemic Haemophilus influenzae infection (16.5 ng/ml) and another one with a septicaemic Pseudomonas aeruginosa infection (44.1 ng/ ml), ProCT values decreased rapidly under appropriate therapy. ProCT seems to be a specific marker of bacterial sepsis in HIV-infected patients, as no increase in other secondary infections could be detected in those patients. A rapid determination of ProCT level could be useful to confirm or refute bacterial sepsis for a better management of febrile HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279723     DOI: 10.1016/s0163-4453(97)90953-1

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Procalcitonin for differential diagnosis of graft rejection and infection in patients with heart and/or lung grafts.

Authors:  S Hammer; F Meisner; P Dirschedl; P Fraunberger; B Meiser; B Reichart; C Hammer
Journal:  Intensive Care Med       Date:  2000-03       Impact factor: 17.440

2.  Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever.

Authors:  Nicolas Penel; Charles Fournier; Stéphanie Clisant; Michèle N'Guyen
Journal:  Support Care Cancer       Date:  2004-02-10       Impact factor: 3.603

3.  Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?

Authors:  I Delèvaux; M André; M Colombier; E Albuisson; F Meylheuc; R-J Bègue; J-C Piette; O Aumaître
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

4.  Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients.

Authors:  Nicolas Bele; Michael Darmon; Isaline Coquet; Jean-Paul Feugeas; Stéphane Legriel; Nadir Adaoui; Benoît Schlemmer; Elie Azoulay
Journal:  BMC Infect Dis       Date:  2011-08-24       Impact factor: 3.090

Review 5.  Procalcitonin--a new indicator of the systemic response to severe infections.

Authors:  W Karzai; M Oberhoffer; A Meier-Hellmann; K Reinhart
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

6.  Sepsis in AIDS patients: clinical, etiological and inflammatory characteristics.

Authors:  João Manoel Silva; Sigrid De Sousa dos Santos
Journal:  J Int AIDS Soc       Date:  2013-01-30       Impact factor: 5.396

7.  Procalcitonin in severe acute respiratory syndrome (SARS).

Authors:  Ai Ping Chua; Kang Hoe Lee
Journal:  J Infect       Date:  2004-05       Impact factor: 6.072

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.